AANEM News Express

AANEM News Express

AANEM Urges FDA to Expedite Development of ALS Treatments

3/28/2013
 
AMA at ALS public hearing
American Medical Association representative testifies at the ALS public hearing.
 
The AANEM submitted comments to the U.S. Food and Drug Administration (FDA), supporting those of The ALS Association and the Muscular Dystrophy Association, urging the FDA to take action to help expedite the development and approval of new treatments for ALS. These comments were in response to the first ever ALS-specific public hearing held by the FDA on February 25, 2013. 
 
Key items addressed in the comments asked the FDA to:
  • Hold follow-up meetings of key stakeholders,
  • Refine preclinical development and clinical trial design in ALS,
  • Understand better the benefit-risk assessment in treatment in ALS patients, and
  • Accelerate review of devices that impact the quality and length of life in ALS patients.
Download the comments (PDF)

The AANEM will continue to work to support more research and improved quality of life for ALS patients.


View Related News Stories:

  Education


Recent AANEM News

Science News: Combined Intravenous Immunoglobulin and Methylprednisolone as Induction Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (OPTIC protocol): A Prospective Pilot Study

Free Checkpoints Available for Member/Non-member CNCTs

Science News: Nerve Ultrasound Improves Detection of Treatment-responsive Chronic Inflammatory Neuropathies

Science News: Cognitive Inhibition Impairments in Presymptomatic C9orf72 Carriers

Remembering Jasper Daube, MD





Advertisement

ABEM

Advertisement

TPP

Advertisement

Devon products